Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction
NCT ID: NCT02054390
Last Updated: 2014-06-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
459 participants
OBSERVATIONAL
2014-02-28
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery
NCT01336959
Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery
NCT02981680
A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
NCT00364390
Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG
NCT06977230
Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass
NCT02096406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. elective percutaneous coronary intervention with angiographically successful stent implantation
Exclusion Criteria
2. renal failure
3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
4. left main coronary artery disease
5. chronic total occlusion
6. high levels of baseline CKMB or troponin
7. any contraindication of aspirin, clopidogrel or ACEi treatment
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Özgür Ulaş Özcan
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara University School Of Medicine, Department of Cardiology
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACEmetsend
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.